Nusinersen versus sham control in infantile-onset spinal muscular atrophy RS Finkel, E Mercuri, BT Darras, AM Connolly, NL Kuntz, J Kirschner, ... New England Journal of Medicine 377 (18), 1723-1732, 2017 | 2002 | 2017 |
Nusinersen versus sham control in later-onset spinal muscular atrophy E Mercuri, BT Darras, CA Chiriboga, JW Day, C Campbell, AM Connolly, ... New England Journal of Medicine 378 (7), 625-635, 2018 | 1246 | 2018 |
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study RS Finkel, CA Chiriboga, J Vajsar, JW Day, J Montes, DC De Vivo, ... The Lancet 388 (10063), 3017-3026, 2016 | 1023 | 2016 |
Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care E Mercuri, RS Finkel, F Muntoni, B Wirth, J Montes, M Main, ES Mazzone, ... Neuromuscular disorders 28 (2), 103-115, 2018 | 898 | 2018 |
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy CA Chiriboga, KJ Swoboda, BT Darras, ST Iannaccone, J Montes, ... Neurology 86 (10), 890-897, 2016 | 660 | 2016 |
Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics RS Finkel, E Mercuri, OH Meyer, AK Simonds, MK Schroth, RJ Graham, ... Neuromuscular Disorders 28 (3), 197-207, 2018 | 614 | 2018 |
Observational study of spinal muscular atrophy type I and implications for clinical trials RS Finkel, MP McDermott, P Kaufmann, BT Darras, WK Chung, ... Neurology 83 (9), 810-817, 2014 | 554 | 2014 |
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III P Kaufmann, JLP Thompson, G Levy, R Buchsbaum, J Shefner, ... Annals of Neurology: Official Journal of the American Neurological …, 2009 | 260 | 2009 |
Prospective cohort study of spinal muscular atrophy types 2 and 3 P Kaufmann, MP McDermott, BT Darras, RS Finkel, DM Sproule, PB Kang, ... Neurology 79 (18), 1889-1897, 2012 | 253 | 2012 |
Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1/2 studies BT Darras, CA Chiriboga, ST Iannaccone, KJ Swoboda, J Montes, ... Neurology 92 (21), e2492-e2506, 2019 | 242 | 2019 |
Revised upper limb module for spinal muscular atrophy: development of a new module ES Mazzone, A Mayhew, J Montes, D Ramsey, L Fanelli, SD Young, ... Muscle & nerve 55 (6), 869-874, 2017 | 236 | 2017 |
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS H Mitsumoto, AM Ulug, SL Pullman, CL Gooch, S Chan, MX Tang, X Mao, ... Neurology 68 (17), 1402-1410, 2007 | 228 | 2007 |
Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy J Montes, MP McDermott, WB Martens, S Dunaway, AM Glanzman, ... Neurology 74 (10), 833-838, 2010 | 199 | 2010 |
Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III AM Glanzman, JM O’Hagen, MP McDermott, WB Martens, J Flickinger, ... Journal of child neurology 26 (12), 1499-1507, 2011 | 187 | 2011 |
Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials E Mercuri, R Finkel, J Montes, ES Mazzone, MP Sormani, M Main, ... Neuromuscular Disorders 26 (2), 126-131, 2016 | 185 | 2016 |
Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year P Kaufmann, MP McDermott, BT Darras, R Finkel, P Kang, M Oskoui, ... Archives of neurology 68 (6), 779-786, 2011 | 176 | 2011 |
Ascitic fluid polymorphonuclear cell count and serum to ascites albumin gradient in the diagnosis of bacterial peritonitis A Albillos, V Cuervas-Mons, I Millan, T Canton, J Montes, C Barrios, ... Gastroenterology 98 (1), 134-140, 1990 | 157 | 1990 |
Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trial P Kaufmann, G Levy, J Montes, R Buchsbaum, AI Barsdorf, V Battista, ... Amyotrophic Lateral Sclerosis 8 (1), 42-46, 2007 | 153 | 2007 |
Developmental milestones in type I spinal muscular atrophy R De Sanctis, G Coratti, A Pasternak, J Montes, M Pane, ES Mazzone, ... Neuromuscular Disorders 26 (11), 754-759, 2016 | 146 | 2016 |
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy MC Pera, G Coratti, N Forcina, ES Mazzone, M Scoto, J Montes, ... BMC neurology 17, 1-10, 2017 | 133 | 2017 |